<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813461</url>
  </required_header>
  <id_info>
    <org_study_id>9766-CL-0016</org_study_id>
    <nct_id>NCT01813461</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of Isavuconazole After a Single Oral Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basilea Pharmaceutica International Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled isavuconazole
      and the routes of excretion and the extent of metabolism of 14C-labeled prodrug BAL8557.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be admitted to and stay in a clinical research unit for 23 days. On Day 1, they
      will receive a single oral dose of BAL8557 and throughout the study period the excretion and
      metabolism of the study drug will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radioactivity in whole blood and in plasma: Area under the concentration-time curve (AUC) from time of dosing to infinity (AUCinf)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity in whole blood and in plasma: AUC from time of dosing to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity in whole blood and in plasma: Maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity in whole blood and in plasma: Time to Attain Cmax (tmax)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity in whole blood and in plasma: Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity in emesis (if applicable)</measure>
    <time_frame>After study drug administration Days 1 up through 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity ratio blood/plasma</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excretion ratio and cumulative excretion of radioactivity in urine</measure>
    <time_frame>Pre-dose and after dosing collection times: 0 to 6, 6 to 12, 12 to 24, and in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until discharge</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excretion ratio and cumulative excretion of radioactivity in feces</measure>
    <time_frame>Pre-dose and after dosing in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until the day of discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of isavuconazole in plasma: AUCinf, AUClast, Cmax, tmax, Apparent body clearance after dosing (CL/F), Apparent volume of distribution (Vz/F), t1/2</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of isavuconazole in urine: Ae, Ae%, CLR</measure>
    <time_frame>Pre-dose and 0 to 6, 6 to 12, 12 to 24, in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until day of discharge</time_frame>
    <description>Amount excreted (Ae), Percent of unchanged drug excreted into the urine (Ae%), Renal clearance (CLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile of isavuconazole and possible metabolites in plasma, urine, and feces</measure>
    <time_frame>8, 24,72, 144, and 312 hours after dosing. If subjects are not discharged on Day 22, samples will be taken at 504 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pharmacokinetics of 14C-labeled Isavuconazole</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>14C-labeled prodrug isavuconazonium sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-labeled prodrug isavuconazonium sulfate</intervention_name>
    <description>oral</description>
    <arm_group_label>14C-labeled prodrug isavuconazonium sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a body weight of at least 45 kg and a body mass index of 18 to 32
             kg/m2, inclusive.

          -  The subject's 12-lead electrocardiogram (ECG) is normal at Screening and Day -1; or,
             if abnormal, the abnormality is not clinically significant, including a QT interval
             corrected for heart rate using Fridericia's formula (QTcF) of 430 msec or less.

          -  The subject's clinical laboratory test results at Screening and Day 1 are within
             normal limits or not clinically significant.

          -  Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must
             be within the normal range.

          -  The subject is surgically sterile or agrees to using a highly effective method of
             contraception to prevent pregnancy during the study and for at least 90 days after
             dosing on Day 1, and the subject agrees to not donate any sperm for at least 90 days
             after dosing on Day 1.

        Exclusion Criteria:

          -  The subject has any clinically significant disease history or condition that precludes
             him from participating in the trial.

          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac
             arrhythmia or torsade de pointes, structural heart disease, or family history of Long
             QT syndrome

          -  The subject has a history of bowel obstruction, swallowing disorder, severe
             gastrointestinal disorders, major gastrointestinal surgery, actively bleeding
             hemorrhoids, or gastric/duodenal ulcers.

          -  The subject has irregular bowel habits (&lt; 1 bowel movement per day).

          -  The subject has had nuclear medicine procedures, computed tomography scans, or
             significant x-rays (other than dental) within the past 12 months, has had significant
             occupational radiation exposure, or participated in a radio-labeled study within the
             last 6 months or participated in more than one radio-labeled study within the last 12
             months.

          -  The subject has a positive test for hepatitis B surface antigen or hepatitis C
             antibodies at Screening or is known to be positive for human immunodeficiency virus
             (HIV).

          -  The subject has/had a symptomatic, viral, bacterial (including upper respiratory
             infection), or fungal (non-cutaneous) infection within 1 week prior to clinic
             admission on Day -1.

          -  The subject has received a vaccination within the last 30 days prior to study drug
             administration.

          -  The subject has a known or suspected allergy to any of the azole class of compounds,
             or a history of multiple and/or severe allergies to drugs or foods (as judged by the
             Investigator), or a history of severe anaphylactic reactions.

          -  The subject has used tobacco or nicotine containing products in the last 6 months.

          -  The subject has had treatment with prescription drugs or complementary and alternative
             medicines within 14 days prior to Day -1, or over-the-counter medication within 1 week
             prior to Day -1, with the exception of occasional use of acetaminophen up to 2 g/day.

          -  The subject has participated in any interventional clinical study or has received any
             investigational agent within 30 days or 5 half-lives, whichever is longer, prior to
             the initiation of Screening.

          -  The subject has had any significant blood loss, donated one unit (450 mL) of blood or
             more, or received a transfusion of any blood or blood products within 60 days or
             donated plasma within 7 days prior to clinic admission on Day -1.

          -  The subject has taken part in strenuous exercise within 3 days prior to dosing on Day
             1.

          -  The subject anticipates an inability to abstain from caffeine or alcohol use for 48
             hours prior to clinic admission on Day -1 and throughout the duration of the study; or
             from grapefruit, grapefruit juice, star fruit, or Seville oranges or any products
             containing these items from 72 hours prior to clinic admission on Day -1 and
             throughout the duration of the study.

          -  The subject has a recent history (within the last 2 years) of drug or alcohol abuse or
             a positive drug screen.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>March 15, 2013</last_update_submitted>
  <last_update_submitted_qc>March 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BAL8557</keyword>
  <keyword>14C-labeled isavuconazole</keyword>
  <keyword>14C-labeled prodrug isavuconazonium sulfate (BAL8557)/([cyano-14C]ASP9766 sulfate)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

